Parents of children with cerebral palsy are among the most determined advocates for their children’s futures, and HBOT has been marketed to this community for decades. The promise is understandable: a therapy that might improve brain function, increase oxygen to damaged tissue, and help a child do more. The reality, as documented in rigorous clinical trials, is considerably more complicated. Understanding this gap honestly, without dismissing parental hope or ignoring real evidence, is the goal of this article. It is one of several brain conditions that may benefit from HBOT currently being explored in clinical research.
What Is Cerebral Palsy?
Cerebral palsy (CP) is a group of permanent movement and posture disorders caused by non-progressive damage to the developing brain, typically occurring before, during, or shortly after birth. The damage may result from oxygen deprivation (hypoxic-ischemic encephalopathy), infection, stroke, or brain malformation. While the initial brain injury does not progress, its effects on motor function, cognition, and other areas evolve as the child develops.
It’s important to understand that CP involves permanent structural brain damage, not ongoing ischemia. The brain tissue that was injured is not waiting for oxygen; the damage is done. This is a fundamental distinction when evaluating whether HBOT, which works primarily by improving oxygen delivery to ischemic but living tissue, is theoretically applicable.
The Theoretical Case for HBOT in CP
Proponents have argued that in CP, there may be areas of “idling neurons,” brain cells that are still alive but functionally dormant due to chronic low-grade hypoperfusion around the area of primary injury. If such neurons exist and if HBOT could activate them, functional improvements might result. This hypothesis, sometimes called the “dormant neuron” theory, drove the initial wave of HBOT interest in CP.
Supporting this hypothesis are reports of increased cerebral blood flow in brain SPECT scans of CP patients after HBOT, and individual reports of improved motor function. Against it is the fact that the dormant neuron concept has not been conclusively validated in humans, and the trial results described below.
The Key Clinical Trial
The most methodologically rigorous study of HBOT for CP was published in The Lancet in 2001 by Collet and colleagues.1 This Canadian randomized controlled trial enrolled 111 children with spastic CP1 and randomly assigned them to receive either HBOT (1.75 ATA, 100% oxygen) or a sham treatment (1.3 ATA, slightly enriched air). Both groups received 40 sessions of 60 minutes each.
The result: both groups improved significantly on multiple functional outcome measures. But there was no statistically significant difference between the HBOT group and the sham group on any primary outcome. The investigators concluded that the improvements in both groups were likely due to non-specific effects of the clinical environment, structured attention, and therapy, not the hyperbaric oxygen treatment itself.
This finding has not been superseded by subsequent trials. Later smaller studies have shown mixed results, but none have met the methodological standard of the Collet trial, and none have clearly shown HBOT to outperform an adequately designed control condition in CP.
Lacey et al. 2012 (PMID: 23071074): N=49 children, 40 sessions at 1.5 ATA. Gross motor function (GMFM): no between-group difference. Trial stopped early, only 0.5 to 1.6% probability of finding a difference if continued. Both HBOT and hyperbaric air groups showed functional improvement.3
Lacey et al., 2012
What the Guidelines Say
The American Academy of Pediatrics, the Cochrane Database, and major pediatric neurology organizations do not recommend HBOT for cerebral palsy.2 The Cochrane review on this topic concluded that there is insufficient evidence to support HBOT for CP and that the potential for harm and the significant cost burden mean it should not be recommended outside of research settings.
What Are the Side Effects and Risks?
For children with CP who have seizure disorders (a common comorbidity), oxygen toxicity-related seizure risk requires careful consideration. HBOT can lower the seizure threshold. Children with CP may also have difficulty tolerating the confined chamber environment, pressurization-related ear discomfort (children must equalize ear pressure, which is challenging for those with limited self-care capacity), and the duration of sessions without movement. These are not insurmountable barriers at experienced pediatric centers, but they add complexity.
The side effects guide covers oxygen toxicity and other general HBOT risks.
What Parents Should Know Before Pursuing HBOT for CP
The financial cost of HBOT for CP is significant. A course of 40 sessions can cost $8,000 to $20,000 or more depending on the facility and location. Insurance rarely covers it for CP. The time commitment, travel, and logistical burden for families are substantial. Against this must be weighed an evidence base that does not support meaningful specific benefit over what a structured, attentive clinical program might provide through non-specific effects.
This is not to say that individual children don’t experience improvements during or after HBOT. But distinguishing between improvements attributable to HBOT, improvements attributable to the intensive structured care and attention during treatment, and improvements reflecting natural developmental trajectories is genuinely difficult without controlled conditions.
The neurological conditions and HBOT article covers the broader neurological evidence base if you want to understand where HBOT has stronger scientific support.
The Financial and Emotional Stakes for Families
For families of children with CP, the financial and emotional investment in HBOT can be enormous. The out-of-pocket cost of a 40-session course can reach $10,000 to $20,000, and families may travel significant distances and disrupt their routines to complete treatment. Against this investment, the controlled evidence suggests no meaningful benefit over sham. This is not a comfortable message to deliver to motivated, loving parents, but it is the honest one.
Money and time spent on HBOT for CP is money and time not available for therapies with better evidence: intensive physical therapy, constraint-induced movement therapy, botulinum toxin management, and educational interventions. For families with limited resources, the evidence-based case for prioritizing these over HBOT is strong.
Respecting Parental Autonomy While Being Honest
Many parents will pursue HBOT for their child with CP despite the evidence. This is understandable: when conventional medicine offers limited options, the drive to try everything is natural and compassionate. If you’re in this situation, the most important things to keep in mind are: continue evidence-based therapies alongside HBOT, don’t substitute HBOT for proven interventions, set specific outcome measures before starting so you can evaluate objectively rather than emotionally, and set a clear decision point (after one course, assess whether measurable improvement occurred before committing to more).
Finding Support Beyond Treatment
For children with CP and their families, support extends far beyond any single treatment. Connecting with CP family networks, accessing educational resources through the Cerebral Palsy Alliance and United Cerebral Palsy organization, working with early intervention specialists, and maintaining realistic long-term planning are all essential components of comprehensive CP management that no single therapy can substitute for. HBOT, if pursued, should be one small element of this broader picture, not the centerpiece of a treatment strategy.
The Historical Context of HBOT and CP
The enthusiasm for HBOT in cerebral palsy has a specific historical origin. In the 1990s and early 2000s, some practitioners observed improvements in children with CP after treating them with HBOT (originally using protocols designed for other conditions), and these reports spread rapidly through parent networks. The “dormant neuron” hypothesis gave the observations a plausible-sounding scientific framework, and marketing by some HBOT centers amplified the claims. The scientific community’s response was the rigorous Collet trial, which found no specific benefit. Despite this, HBOT for CP continues to be marketed and pursued by families who are understandably motivated to try every possible intervention.
Understanding this history helps explain why the disconnect between parental belief and scientific evidence persists: the initial reports were genuine observations (improvements did occur), but the controlled trial showed these improvements happen with or without HBOT, making the therapy itself unnecessary as an explanation.
Frequently Asked Questions
If HBOT doesn't work for CP, why do some families report improvement?
Several factors may contribute to reported improvements that are not specific to HBOT: the intensive structured care during a treatment course, increased parental attention and engagement, natural developmental progress during the period of treatment, and regression to the mean (children who are assessed during a period of relative difficulty may naturally improve). The sham-controlled trial found that sham treatment produced similar levels of improvement, which is the strongest evidence that specific HBOT effects are not responsible.
Are there any CP subtypes or situations where HBOT might be more justified?
Some researchers have suggested that CP associated with white matter injury (periventricular leukomalacia) might be more amenable to HBOT than other CP types, due to the potential for white matter recovery with improved oxygenation. This is speculative and not supported by subset analyses from controlled trials.
What are evidence-based alternatives for CP motor improvement?
Intensive physical therapy, constraint-induced movement therapy (CIMT), botulinum toxin for spasticity, intrathecal baclofen for severe spasticity, and selective dorsal rhizotomy (SDR) for appropriate candidates all have stronger evidence bases for improving motor function in CP than HBOT. These should be the priority for families.
References
- Collet JP, et al. “Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial.” Lancet. 2001;357(9256):582-586. DOI: 10.1016/S0140-6736(00)04054-4
- Cochrane Review. “Hyperbaric oxygen therapy for cerebral palsy.” Cochrane Database Syst Rev. Cochrane Library
- Lacey JL, et al. “Placebo-controlled trial of hyperbaric oxygen and air for cerebral palsy: effect on disability.” Dev Med Child Neurol. 2012;54(11):1000-1009. PMID: 23071074. DOI: 10.1111/j.1469-8749.2012.04420.x
- Jovanovic et al. 2017. Observational study, N=52 children with CP. 120 sessions at 1.55 ATA.
- 2022 Systematic Review. “Hyperbaric oxygen in children with cerebral palsy.” PMC9565562. PMC9565562
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
